Taiho Oncology

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Taiho Oncology sits in the top decile of US sponsors by registered trial count (#363 of 15,742 sponsors by registered trial count).

52 total trials 7 currently recruiting 23 completed early-phase tilt top decile by trial count

Taiho Oncology: 52 sponsored US clinical trials, 7 recruiting.

Taiho Oncology sponsors 52 registered US clinical trials on ClinicalTrials.gov, 7 of them currently recruiting, and 23 completed. 8 of these trials are in Phase 3-4 (later-stage) and 43 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 4 trials.

Top-decile sponsor footprint

Taiho Oncology ranks in the top decile of sponsors by registered trial count (#363 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

23 of 40 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (57.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

What is open in the Taiho Oncology pipeline

7 recruiting of 52 indexed (13% open); 23 completed (44%).

Phase mix: 8 late (III/IV) vs 43 early (I/II) (early-phase heavy).

Top condition: Acute Myeloid Leukemia (4 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Taiho Oncology: open-pipeline peers nationwide

Peers matched on 52 registered trials and 13% open enrollment, not the therapeutic-area sidebar.

Taiho Oncology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 0%5%10%15% Total trials Recruiting share Taiho OncologyAlbany Medical CollegeBurzynski Research InstituteDr. Reddy's Laboratories LimitedPTC TherapeuticsUniversity of MichiganWayne State UniversityCase Comprehensive Cancer CenterBeth Israel Deaconess Medical Center
Taiho Oncology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Taiho Oncology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 52 trials (± recruiting share)

Sponsors near 13% open enrollment (± trial volume)

What to do with this Taiho Oncology page

52 registered trials is a research-attention snapshot, not an endorsement of Taiho Oncology or any single study.

  • 7 of Taiho Oncology's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Acute Myeloid Leukemia is the condition Taiho Oncology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Taiho Oncology pipeline card: 52 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.